Compare · AARD vs AXSM
AARD vs AXSM
Side-by-side comparison of Aardvark Therapeutics Inc. (AARD) and Axsome Therapeutics Inc. (AXSM): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AARD and AXSM operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- AXSM is the larger of the two at $7.59B, about 228.3x AARD ($33.3M).
- AARD has been more active in the news (9 items in the past 4 weeks vs 4 for AXSM).
- AXSM has more recent analyst coverage (25 ratings vs 17 for AARD).
- Company
- Aardvark Therapeutics Inc.
- Axsome Therapeutics Inc.
- Price
- -
- -
- Market cap
- $33.3M
- $7.59B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2025
- 2015
- News (4w)
- 9
- 4
- Recent ratings
- 17
- 25
Axsome Therapeutics Inc.
Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. Its product pipeline includes AXS-05 for the treatment major depressive disorder and resistant depression disorders; and that is in the Phase III clinical trial for the treatment of Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation. The company is also developing AXS-07 for the treatment of migraine; AXS-12 for the treatment of narcolepsy; and AXS-14 for the treatment of fibromyalgia. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.
Latest AARD
- SEC Form 10-Q filed by Aardvark Therapeutics Inc.
- Chief Executive Officer Lee Tien-Li was granted 793,951 stock options and returned 793,951 stock options to the company (SEC Form 4)
- Officer Sun Nelson was granted 304,094 stock options and returned 304,094 stock options to the company (SEC Form 4)
- Chief Medical Officer Jaiman Manasi was granted 374,560 stock options and returned 374,560 stock options to the company (SEC Form 4)
- Aardvark Therapeutics downgraded by Raymond James
- SEC Form 8-K filed by Aardvark Therapeutics Inc.
- Aardvark Therapeutics Reports Exploratory Data from the Terminated HERO and Open-Label Extension Trials
- SEC Form 8-K filed by Aardvark Therapeutics Inc.
- Aardvark Therapeutics Announces FDA Has Lifted the Clinical Hold on ARD-101 for the Treatment of Prader-Willi Syndrome and Will Host Webcast to Review the Available Exploratory Phase 3 HERO/OLE Data
- AARD UPCOMING DEADLINE: Levi & Korsinsky Alerts Aardvark Therapeutics, Inc. Stockholders of Securities Class Action - Contact the Firm
Latest AXSM
- Axsome Therapeutics to Participate in Upcoming Investor Conferences
- SEC Form 10-Q filed by Axsome Therapeutics Inc.
- Axsome Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits
- Axsome Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update
- Axsome Therapeutics to Report Third Quarter 2026 Financial Results on November 2
- Truist resumed coverage on Axsome Therapeutics with a new price target
- Axsome Therapeutics Announces Results of the Shared Goals Survey of Caregivers of Patients with Alzheimer’s Disease Agitation Presented at Psych Congress 2026 in Connection with World Alzheimer’s Day
- Axsome Therapeutics Presents Ten Posters Exemplifying its Innovative Psychiatry and Neurology Portfolio at Psych Congress 2026
- Chief Operating Officer Jacobson Mark L. sold $2,086,500 worth of shares (10,000 units at $208.65) as part of a pre-agreed trading plan and exercised 10,000 shares at a strike of $12.95 (SEC Form 4)
- Axsome Therapeutics to Participate in Upcoming Investor Conferences